摘要
背景与目的:化疗是治疗转移性乳腺癌的主要方法之一,蒽环类和紫杉类药物是乳腺癌化疗最有效的药物。但是很多患者在辅助治疗或者一线救援方案中已经用过这两类药物。长春瑞滨和吉西他滨也是乳腺癌化疗的有效药物之一。本研究目的是观察吉西他滨联合长春瑞滨治疗转移性乳腺癌的疗效与毒副作用。方法:34例接受过蒽环和/或紫杉类治疗的转移性乳腺癌患者,接受吉西他滨联合长春瑞滨方案治疗,吉西他滨1000mg/m2静脉滴注30min,d1、d8,长春瑞滨25mg/m2静脉推注,d1、d8,每21天重复一次。结果:全组34例共完成109个周期的治疗,中位数3周期,范围1～6周期;均可评价疗效。没有完全缓解的病例,部分缓解9例,病情稳定19例,病情进展6例,客观有效率(完全缓解+部分缓解)26.47%;中位疾病进展时间5.4个月,中位生存期17.8个月;1年生存率68%(95%可信区间为50%～86%),2年生存率46%(95%可信区间为26%～66%)。不良反应主要为Ⅰ～Ⅱ度骨髓抑制、末梢神经毒性及胃肠道反应,部分患者出现轻度的皮疹及肝功能损害。结论:吉西他滨联合长春瑞滨方案治疗转移性乳腺癌患者,初步观察有一定的疗效,其毒副作用患者可以耐受。
BACKGROUND ＆ OBJECTIVE： Chemotherapy is one of major treatments of metastatic breast cancer. Anthracyclines and taxanes are usually considered as the most active agents in breast cancer and are often used as adjuvant or first-line therapy. Gemcitabine and vinorelbine are active agents in breast cancer. This study was to evaluate the efficacy of gemcitabine combined vinorelbine on the patients with metastatic breast cancer, who had previously received treatment of anthracyclines and/or taxanes. METHODS. Thirty-four patients with metastatic breast cancer, who had been previously treated with anthracyclines alone or with taxanes, were enrolled. The patients received 30-minute intravenous injection of gemcitabine （1 000 mg/m^2） and intravenous bolus injection of vinorelbine（25 mg/m^2） on Days 1 and 8; the regimen was repeated every 21 days. RESULTS, A total of 109 cycles were given to the 34 patients （median, 3 cycles; range, 1-6 cycles）. The treatment responses were evaluabie in all patients. Of the 34 patients, 9 achieved partial remission （PR）, 19 had stable disease （SD）, 6 had progressive disease （PD）; the response rate was 26.47%. The median time to progression was 5.4 months. The median overall survival was 17.8 months. The 1-year overall survival rate was 68% [95% confidence interval （CI）. 50%-86%], the 2-year overall survival rate was 46% （95% CI： 26%- 66% ）. The major adverse events were grade Ⅰ - Ⅱ myelosuppression, peripheral neurologic toxicities, nausea and vomiting. Some patients had rash and hepatic dysfunction. CONCLUSION, The combination of gemcitabine and vinorelbine is an effective and well tolerated regimen for the patients with metastatic breast cancer.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2007年第12期1373-1376,共4页
Chinese Journal of Cancer
